Skip to main content

Advertisement

SpringerLink
Log in

In silico molecular studies of natural compounds as possible anti-Alzheimer’s agents: ligand-based design

  • Original Article
  • Published:
Network Modeling Analysis in Health Informatics and Bioinformatics Aims and scope Submit manuscript

Abstract

Alzheimer disease (AD) is the most common form of dementia contributing to about 60–70% of cases. β-Site amyloid precursor protein cleaving enzyme-1 (BACE1) plays an important role in the onset of AD and has become one of the important drug targets for AD. This approach has led to the development of promising BACE1 inhibitors, many of which are going through different phases of clinical trials. Nonetheless, the high failure rate of lead drug candidates targeting BACE1 brought to the forefront the need for finding new drugs to uncover the mystery behind AD. This study focused on virtual screening of ~ 33,000 natural compounds to find potential BACE1 inhibitors. Multiple ligands pharmacophore model was generated using PHASE to screen retrieved compounds against a four-site (ADDR) hypothesis. Molecular docking was performed to predict the binding status of the natural compounds. Based on binding affinity, the top eight compounds were chosen for further analysis. The docked complexes were analyzed for binding free energy using PRIME MM/GBA calculation. The compounds were filtered for drug-likeness using ADME/TOX (absorption, distribution, metabolism, excretion and toxicity) prediction. AutoQSAR (automated quantitative structure activity relationship) was used to build a model for the prediction of compounds bioactivities. Despite retrieving a large number of compounds with favorable binding affinity, only a few were selected to be promising based on their ADME/TOX proprieties, binding free energy and predicted pIC50. This study identified four natural compounds (NPC469686, NPC262328, NPC29763 and NPC86744) as novel BACE1 inhibitors. The insights obtained from this study could be employed to produce next-generation drug for AD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  • Ali MY, Jannat S, Jung HA, Choi RJ, Roy A, Choi JS (2016) Anti-Alzheimer’s disease potential of coumarins from Angelica decursiva and Artemisia capillaris and structure–activity analysis. Asian Pacific J Trop Med 9(2):103–111. https://doi.org/10.1016/j.apjtm.2016.01.014

    Article  Google Scholar 

  • Banerjee P, Eckert AO, Schrey AK, Preissner R (2018) ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res 46(W1):W257–W263. https://doi.org/10.1093/nar/gky318

    Article  Google Scholar 

  • Botteri G, Salvadó L, Gumà A, Lee Hamilton D, Meakin P, Montagut G, Ashford M, Ceperuelo-Mallafré V et al (2018) The BACE1 product sAPPβ induces ER stress and inflammation and impairs insulin signaling. Metabolism 85:59–75. https://doi.org/10.1016/j.metabol.2018.03.005

    Article  Google Scholar 

  • Brodney MA, Barreiro G, Ogilvie K et al (2012) Spirocyclic sulfamides as β-secretase 1 (bace-1) inhibitors for the treatment of Alzheimer’s disease: utilization of structure based drug design, watermap, and CNS penetration studies to identify centrally efficacious inhibitors. J Med Chem 55:9224–9239

    Article  Google Scholar 

  • Brühlmann C, Ooms F, Carrupt PA, Testa B, Catto M, Leonetti F, Altomare C, Carotti A (2001) Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase. J Med Chem 44(19):3195–3198

    Article  Google Scholar 

  • Burns A, Iliffe S (2009) Alzheimer’s disease. BMJ 338:b158. https://doi.org/10.1136/bmj.b158

    Article  Google Scholar 

  • Chen CY (2013) A novel integrated framework and improved methodology of computer-aided drug design. Curr Top Med Chem 13(9):965–988

    Article  Google Scholar 

  • Cummings J, Lee G, Ritter A et al (2018) Alzheimer’s disease drug development pipeline: 2018. Alzheimers Dement 4:195–214

    Article  Google Scholar 

  • Danon J, Reekie T, Kassiou M (2019) Challenges and opportunities in central nervous system drug discovery. Trend Chem 1(6):612–624. https://doi.org/10.1016/j.trechm.2019.04.009

    Article  Google Scholar 

  • De Castro C, Costa P, Laktin G, de Carvalho P, Geraldo R, de Moraes J, Pinto P et al (2015) Cardamonin, a schistosomicidal chalcone from Piper aduncum L. (Piperaceae) that inhibits Schistosoma mansoni ATP diphosphohydrolase. Phyto 22:921–928. https://doi.org/10.1016/j.phymed.2015.06.009

    Article  Google Scholar 

  • Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, Friesner RA (2006) PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Molec Design 20(11):647–671

    Article  Google Scholar 

  • Dixon SL, Duan J, Smith E, Von-Bargen CD, Sherman W, Repasky MP (2016) AutoQSAR: an automated machine learning tool for best-practice quantitative structure–activity relationship modeling. Future Med Chem 8:1825–1839

    Article  Google Scholar 

  • Duan J, Dixon SL, Lowrie JF, Sherman W (2010) Analysis and comparison of 2D fingerprints; insights into database screening performance using eight fingerprint method. J Molec Graph Model 29:157–170

    Article  Google Scholar 

  • Elekofehinti OO, Ejelonu O, Iwaloye O et al (2018) Discovery of potential visfatin activators using in silico docking and ADME predictions as therapy for type 2 diabetes. Beni-suef Univ J Basic Appl Sci 7(2):241–249

    Article  Google Scholar 

  • Feng RM (2002) Assessment of blood–brain barrier penetration: in silico, in vitro and in vivo. Curr Drug Metab 3:647–665

    Article  Google Scholar 

  • Foraker J, Millard SP, Leong L et al (2015) The APOE gene is differentially methylated in Alzheimer’s disease. J Alzheimers Dis 48(3):745–755

    Article  Google Scholar 

  • Fukunishi Y (2009) Structure-based drug screening and ligand-based drug screening with machine learning. Comb Chem High Throughput Screen 12(4):397–408

    Article  Google Scholar 

  • Ghosh AK, Osswald HL (2010) BACE1 (beta-secretase) inhibitors for the treatment of Alzheimer’s disease. Chem Soc Rev 43(19):6765–6813

    Article  Google Scholar 

  • Ghosh AK, Brindisi M, Yen YC, Cardenas EL, Ella-Menye JR, Kumaragurubaran N, Huang X, Tang J, Mesecar AD (2017) AD design, synthesis, and X-ray structural studies of BACE1 inhibitors containing substituted 2-oxopiperazines as P1 ’–P2’ ligands. Bioorg Med Chem Lett 27:2432–2438

    Article  Google Scholar 

  • Gombar VK, Silver IS, Zhao Z (2003) Role of ADME characteristics in drug discovery and their in silico evaluation: in silico screening of chemicals for their metabolic stability. Curr Top Med Chem 3(11):1205–1225. https://doi.org/10.2174/1568026033452014

    Article  Google Scholar 

  • Haapasalo A, Hiltunen M (2018) A report from the 8th Kuopio Alzheimer symposium. Neurodegener Dis Manag 8(5):289–299

    Article  Google Scholar 

  • Hartsuck JA, Tang J (1972) The carboxylate ion in the active center of pepsin. J Biol Chem 247:2575–2580

    Google Scholar 

  • Harun A, James RM, Lim SM et al (2011) BACE1 inhibitory activity of fungal endophytic extracts from Malaysian medicinal plants. BMC Compl Alter Med 11:79

    Article  Google Scholar 

  • Isabella AG, Camila SM, Laurent ED (2014) Receptor-Ligand molecular docking. Biophys Rev 6(1):75–87

    Article  Google Scholar 

  • Iwaloye O, Elekofehinti OO, Babatomiwa K, Fadipe TM (2020) In silico molecular studies of selected compounds as novel inhibitors for phosphodiesterase-5 (PDE5) in the management of erectile dysfunction. J Comput Sci Syst Biol 13:307

    Google Scholar 

  • Kennedy T (1997) Managing the drug discovery/development interface. Drug Discov Today 2(10):436–444. https://doi.org/10.1016/s1359-6446(97)01099-4

    Article  Google Scholar 

  • Kumju Y, Mira J (2019) Biological evaluation and docking analysis of potent BACE1 inhibitors from Boesenbergia rotunda. Nutrients 11(3):662. https://doi.org/10.3390/nu11030662

    Article  Google Scholar 

  • Lalitha K, Rajendra KS (2006) Selective determination of mimosine and its dihydroxypyridinyl derivative in plant systems. Amino Acids 31:279–287

    Article  Google Scholar 

  • Lenz GR (1999) Technical problems in getting results. In: Haberman AB, Lenz GR, Vaccaro DE (Eds) From data to drugs: strategies forbenefiting from the new drug discovery technologies. pp 95–114

  • Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46(13):3–26. https://doi.org/10.1016/S0169-409X(00)00129-0

    Article  Google Scholar 

  • Loy CT, Schofield PR, Turner AM, Kwok JB (2014) Genetics of dementia. Lancet 383(9919):828–840. https://doi.org/10.1016/s0140-6736(13)60630-3

    Article  Google Scholar 

  • Maffucci I, Hu X, Fumagalli V, Contini A (2018) An efficient implementation of the Nwat MMGBSA method to rescore docking results in medium-throughput virtual screenings. Front Chem 6:43

    Article  Google Scholar 

  • Meyer EA, Castellano RK, Diederich F (2003) Interactions with aromatic rings in chemical and biological recognition. Angew Chem Int Ed Engl 42(11):1210–1250. https://doi.org/10.1002/anie.200390319

    Article  Google Scholar 

  • Mezei M (2013) A new method for mapping macromolecular topography. J Mol Graph Model 21:463–472. https://doi.org/10.1016/S1093-3263(02)00203-6

    Article  Google Scholar 

  • Moussa-Pacha NM, Abdin SM, Omar HA, Alniss H, Al-Tel TH (2019) BACE1 inhibitors: current status and future directions in treating Alzheimer’s disease. Med Res Rev 40:339–384. https://doi.org/10.1002/med.21622

    Article  Google Scholar 

  • Mullard A (2017) BACE inhibitor bust in Alzheimer trial. Nat Rev Drug Discov 16(3):155–155

    Google Scholar 

  • Ohno M (2016) Alzheimer’s therapy targeting the beta-secretase enzyme BACE1: benefits and potential limitations from the perspective of animal model studies. Brain Res Bull 126(2):183–198

    Article  Google Scholar 

  • Olsson MHM, Søndergard CR, Rostkowski M, Jensen JH (2011) PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions. J Chem Theor Comput 7:525–537

    Article  Google Scholar 

  • Oprea TI, Davis AM, Teague SJ, Leeson PD (2001) Is there a difference between leads and drugs? A historical perspective. J Chem Inf Comput Sci 41(5):1308–1315. https://doi.org/10.1021/ci010366a

    Article  Google Scholar 

  • Pajouhesh H, Lenz G (2005) Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2:541–553

    Article  Google Scholar 

  • Pinhiero AA, Silva KR, Silva AES et al (2015) In silico identification of novel potential bace-1 inhibitors for Alzheimer’s disease treatment: molecular docking, pharmacophore modeling and activity and synthetic accessibility predictions. B J Pharm Res 7:217–229

    Article  Google Scholar 

  • Piton M, Hirtz C, Desmetz C et al (2018) Alzheimer’s disease: advances in drug development. J Alzheimers Dis 65(1):3–13

    Article  Google Scholar 

  • Prime (2018) version 3.9, Schrodinger, LLC, New York, NY

  • Rampogu S, Baek A, Zeb A, Lee KW (2018) Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations. BMC Cancer 18(1):264

    Article  Google Scholar 

  • Reiss AB, Arain HA, Stecker MM et al (2018) Amyloid toxicity in Alzheimer’s disease. Rev Neurosci 29(6):613–627

    Article  Google Scholar 

  • Schrödinger Release (2018) 2018-4: LigPrep 2018 Schrödinger. LLC, New York, NY

  • Schrödinger Release (2018) 2018-4: QikProp 2018 Schrödinger, LLC, New York, NY

  • Singh KD, Muthusamy K (2013) Molecular modeling, quantum polarized ligand docking and structure-based 3D-QSAR analysis of the imidazole series as dual AT(1) and ET(A) receptor antagonists. Acta Pharmacol Sin 34(12):1592–1606. https://doi.org/10.1038/aps.2013.129

    Article  Google Scholar 

  • Schrödinger Suite (2012) Protein Preparation Wizard; Epik version 2.3, Schrödinger, LLC, NewYork, NY, 2012; Impact version 5.8, Schrödinger, LLC, New York, NY, 2012; Prime version 3.1, Schrödinger, LLC, New York, NY

  • Sun H, Li Y, Shen M, Tian S, Xu L, Pan P et al (2014) Assessing the performance of the MM/PBSA and MM/GBSA methods. 5, improved docking performance using high solute dielectric constant MM/GBSA and MM/PBSA rescoring. Phys Chem Chem Phys 16:22035–22045

    Article  Google Scholar 

  • Todd S, Barr S, Roberts M, Passmore AP (2013) Survival in dementia and predictors of mortality: a review. Intern J Geriatr Psychiatr 28(11):1109–1124. https://doi.org/10.1002/gps.3946

    Article  Google Scholar 

  • Xian Z, Peng Z, Weidong H, Chu Q, Shangying C, Lin T, Yali W, Ying T et al (2018) NPASS: natural product activity and species source database for natural product research, discovery and tool development. Nucleic Acids Res 46:217–222. https://doi.org/10.1093/nar/gkx1026

    Article  Google Scholar 

Download references

Acknowledgements

We acknowledge the technical support received from Computational Biologists at Bioinformatics and Molecular Biology Unit, Department of Biochemistry, Federal University of Technology Akure, Ondo State, Nigeria.

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Bioinformatics and Molecular Biology Unit, Department of Biochemistry, Federal University of Technology Akure, Akure, Ondo State, Nigeria

    Opeyemi Iwaloye, Olusola Olalekan Elekofehinti, Abiola Ibrahim Momoh & Esther Opeyemi Ariyo

  2. Adekunle Ajasin University, Akungba Akoko, Ondo State, Nigeria

    Kikiowo Babatomiwa

Authors
  1. Opeyemi Iwaloye
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olusola Olalekan Elekofehinti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Abiola Ibrahim Momoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kikiowo Babatomiwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Esther Opeyemi Ariyo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Opeyemi Iwaloye.

Ethics declarations

Conflict of interest

The authors of this manuscript declare that they have no completing interests.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Iwaloye, O., Elekofehinti, O., Momoh, A.I. et al. In silico molecular studies of natural compounds as possible anti-Alzheimer’s agents: ligand-based design. Netw Model Anal Health Inform Bioinforma 9, 54 (2020). https://doi.org/10.1007/s13721-020-00262-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s13721-020-00262-7

Keywords

Search

Navigation